Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib
and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.